Hepatitis C-vírus-fertozés és hepatocarcinogenesis

Berta Evelin, Egresi Anna, Bacsárdi Anna, Gáspár Zsófia, G. Lengyel, K. Hagymási

Research output: Article

Abstract

Hepatitis C virus infection causes approximately 4 million new infections worldwide, and 399 000 deaths due to its complications, cirrhosis and hepatocellular carcinoma (HCC). Microenvironmental changes, chronic inflammation, oxidative stress, endoplasmic reticulum stress caused by HCV infection, via genetic and epigenetic changes can result in primary liver cancer during decades. The direct oncogenic property of HCV is wellknown. The transforming effect of four HCV proteins (core, NS3, NS4B, NS5A) has been proven. Effective antiviral therapy, sustained viral response decreases the HCV-related general and liver-related mortality. Interferon-based therapy reduces the risk of HCC development. Shorter therapy with direct acting antiviral agents (DAA) has higher efficacy, fewer side-effects. Publications have reported the unexpected effects of DAA. The authors review the articles focusing on the occurrence of HCC in connection with DAA therapies. There is a need for prospective, multicentric studies with longer follow-up to examine the risk of HCC formation. After antiviral therapy, HCC surveillance is of high importance which means abdominal ultrasound every 3-6-12 months in sustained viral response patients as well.

Original languageHungarian
Pages (from-to)846-853
Number of pages8
JournalOrvosi hetilap
Volume160
Issue number22
DOIs
Publication statusPublished - jún. 1 2019

Fingerprint

Virus Diseases
Hepacivirus
Antiviral Agents
Hepatocellular Carcinoma
Therapeutics
Endoplasmic Reticulum Stress
Liver Neoplasms
Infection
Epigenomics
Interferons
Publications
Oxidative Stress
Fibrosis
Prospective Studies
Inflammation
Mortality
Liver

Keywords

  • Direct acting antiviral agents
  • Hepatitis C virus infection
  • Hepatocellular carcinoma
  • Interferon-based antiviral therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hepatitis C-vírus-fertozés és hepatocarcinogenesis. / Evelin, Berta; Anna, Egresi; Anna, Bacsárdi; Zsófia, Gáspár; Lengyel, G.; Hagymási, K.

In: Orvosi hetilap, Vol. 160, No. 22, 01.06.2019, p. 846-853.

Research output: Article

Evelin, Berta ; Anna, Egresi ; Anna, Bacsárdi ; Zsófia, Gáspár ; Lengyel, G. ; Hagymási, K. / Hepatitis C-vírus-fertozés és hepatocarcinogenesis. In: Orvosi hetilap. 2019 ; Vol. 160, No. 22. pp. 846-853.
@article{c72062969b5340138a4fdaebf8c69c56,
title = "Hepatitis C-v{\'i}rus-fertoz{\'e}s {\'e}s hepatocarcinogenesis",
abstract = "Hepatitis C virus infection causes approximately 4 million new infections worldwide, and 399 000 deaths due to its complications, cirrhosis and hepatocellular carcinoma (HCC). Microenvironmental changes, chronic inflammation, oxidative stress, endoplasmic reticulum stress caused by HCV infection, via genetic and epigenetic changes can result in primary liver cancer during decades. The direct oncogenic property of HCV is wellknown. The transforming effect of four HCV proteins (core, NS3, NS4B, NS5A) has been proven. Effective antiviral therapy, sustained viral response decreases the HCV-related general and liver-related mortality. Interferon-based therapy reduces the risk of HCC development. Shorter therapy with direct acting antiviral agents (DAA) has higher efficacy, fewer side-effects. Publications have reported the unexpected effects of DAA. The authors review the articles focusing on the occurrence of HCC in connection with DAA therapies. There is a need for prospective, multicentric studies with longer follow-up to examine the risk of HCC formation. After antiviral therapy, HCC surveillance is of high importance which means abdominal ultrasound every 3-6-12 months in sustained viral response patients as well.",
keywords = "Direct acting antiviral agents, Hepatitis C virus infection, Hepatocellular carcinoma, Interferon-based antiviral therapy",
author = "Berta Evelin and Egresi Anna and Bacs{\'a}rdi Anna and G{\'a}sp{\'a}r Zs{\'o}fia and G. Lengyel and K. Hagym{\'a}si",
year = "2019",
month = "6",
day = "1",
doi = "10.1556/650.2019.31411",
language = "Hungarian",
volume = "160",
pages = "846--853",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "22",

}

TY - JOUR

T1 - Hepatitis C-vírus-fertozés és hepatocarcinogenesis

AU - Evelin, Berta

AU - Anna, Egresi

AU - Anna, Bacsárdi

AU - Zsófia, Gáspár

AU - Lengyel, G.

AU - Hagymási, K.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Hepatitis C virus infection causes approximately 4 million new infections worldwide, and 399 000 deaths due to its complications, cirrhosis and hepatocellular carcinoma (HCC). Microenvironmental changes, chronic inflammation, oxidative stress, endoplasmic reticulum stress caused by HCV infection, via genetic and epigenetic changes can result in primary liver cancer during decades. The direct oncogenic property of HCV is wellknown. The transforming effect of four HCV proteins (core, NS3, NS4B, NS5A) has been proven. Effective antiviral therapy, sustained viral response decreases the HCV-related general and liver-related mortality. Interferon-based therapy reduces the risk of HCC development. Shorter therapy with direct acting antiviral agents (DAA) has higher efficacy, fewer side-effects. Publications have reported the unexpected effects of DAA. The authors review the articles focusing on the occurrence of HCC in connection with DAA therapies. There is a need for prospective, multicentric studies with longer follow-up to examine the risk of HCC formation. After antiviral therapy, HCC surveillance is of high importance which means abdominal ultrasound every 3-6-12 months in sustained viral response patients as well.

AB - Hepatitis C virus infection causes approximately 4 million new infections worldwide, and 399 000 deaths due to its complications, cirrhosis and hepatocellular carcinoma (HCC). Microenvironmental changes, chronic inflammation, oxidative stress, endoplasmic reticulum stress caused by HCV infection, via genetic and epigenetic changes can result in primary liver cancer during decades. The direct oncogenic property of HCV is wellknown. The transforming effect of four HCV proteins (core, NS3, NS4B, NS5A) has been proven. Effective antiviral therapy, sustained viral response decreases the HCV-related general and liver-related mortality. Interferon-based therapy reduces the risk of HCC development. Shorter therapy with direct acting antiviral agents (DAA) has higher efficacy, fewer side-effects. Publications have reported the unexpected effects of DAA. The authors review the articles focusing on the occurrence of HCC in connection with DAA therapies. There is a need for prospective, multicentric studies with longer follow-up to examine the risk of HCC formation. After antiviral therapy, HCC surveillance is of high importance which means abdominal ultrasound every 3-6-12 months in sustained viral response patients as well.

KW - Direct acting antiviral agents

KW - Hepatitis C virus infection

KW - Hepatocellular carcinoma

KW - Interferon-based antiviral therapy

UR - http://www.scopus.com/inward/record.url?scp=85067393957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067393957&partnerID=8YFLogxK

U2 - 10.1556/650.2019.31411

DO - 10.1556/650.2019.31411

M3 - Article

C2 - 31131608

VL - 160

SP - 846

EP - 853

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 22

ER -